German firms' red card at medical technology aids plans
This article was originally published in Clinica
Access to medical technical aids in Germany is set to change dramatically under plans laid out in the draft health financing reform 2006, says industry association BVMed. Following its participation at a hearing last week on the proposed changes, the association is running an information campaign to highlight the prospective law's shortcomings in three areas in particular. On the first, the industry says "yes" to full patient choice of a range of quality local services and products provided under fully competitive conditions. And it says "no" to both restricted choice of aids and to competition based on price alone. These latter two opinions are printed on red cards (while the positive reaction is printed on green).
You may also be interested in...
Following closely on the heels of a medical device tax repeal win, AdvaMed CEO Scott Whitaker sat down to discuss how the industry advocacy group ended the Obamacare excise tax and what it has in store for 2020.
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.
The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital.